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ABSTRACT
Drugs are known to cause various adverse drug reactions involving major organ systems. Skin-related adverse reactions are very common and range 
from a simple rash to life-threatening condition like Stevens-Johnson syndrome. Various drugs are known to cause skin reactions which include 
antiepileptics, analgesics, antibiotics, and proton-pump inhibitors. Nonsteroidal anti-inflammatory drugs causing life-threatening conditions such 
as Stevens-Johnson syndrome and toxic epidermal necrolysis are very rare and only few case reports are published. Hence, we report a case of 
Aceclofenac-induced Stevens-Johnson syndrome after single time administration in a tertiary care hospital in India.
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INTRODUCTION
Medical treatment is very challenging as every day the treating 
physician experiences new challenges in treating various conditions 
as well as encounters new adverse drug reactions to medications. 
Adverse cutaneous drug reactions are very common in clinical 
practice, but it often goes unreported. Adverse cutaneous drug 
reaction is defined as any reaction that causes damage to skin, skin 
appendages, and mucous membrane and all adverse effects related 
to drug eruption are included irrespective of the etiology [1]. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause 
many adverse reactions which include nausea, vomiting, dyspepsia, 
gastric ulcers, and cutaneous reactions pruritus, morbilliform rashes, 
urticaria, and photosensitivity [2]. Sometimes, NSAIDs cause life-
threatening conditions such as Stevens-Johnson’s syndrome and toxic 
epidermal necrolysis which are very rare and only few cases have 
been reported so far in the literature [3]. Hence, we report a rare case 
of Aceclofenac-induced Stevens-Johnson’s syndrome in a tertiary care 
patient in Southern India.
CASE REPORT
Informed consent was taken from the patient. The patient was treated by 
a general practitioner with paracetamol and Aceclofenac on December 
25th, 2016 for severe fever and body pains with myalgia. Later, December 
26th, 2016 patient came to our hospital with complaints of oral lesions 
with fluid-filled blisters all over the body with skin peeling over the 
upper chest and trunk. Multiple purpuric macules were also noted all 
over the trunk with additional fluid-filled bullae over the face/nails 
and scalp. The patient also had complaints of burning sensation in eyes 
associated with lacrimation and redness along with burning sensation 
of palms and soles. History also revealed one episode of vomiting. No 
history of similar episodes in the past or any allergy. The patient was 
not on any other medications. Immediately, tablet Aceclofenac was 
suspected as the cause of adverse drug reaction ruling out other causes. 
Diagnosis of Aceclofenac-induced Stevens-Johnson syndrome was made 
and the patient was treated with fusidic acid ointment and fluticasone 
ointment thrice daily to be applied locally till the lesions subside. He 
was also started on Wysolone 20 mg oral tablet in the morning along 
with candid mouthwash. He was also started with ciprofloxacin eye 
drops along with other supportive measures. Moreover, the patient 
was asked to review after 2 weeks. The patient showed significant 
improvement on his next visit.
DISCUSSION
Stevens-Johnson syndrome is very rare and is said to be a life-
threatening skin condition. Incidence ranges from 2.6 to 7.1 persons per 
million populations per year in the United States [4]. Various drugs are 
implicated in causing Stevens-Johnson syndrome and incidence ranges 
from 75 to 90% for drug-induced etiology [5]. The most common drugs 
implicated include NSAIDs, anti-epileptics, and antimicrobials. Based on 
the body surface area involved Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) is classified with former involving < 10% and 
later involving > 30%, respectively [5]. Sometimes, both these conditions 
overlap together which is called SJS-TEN overlap. It is diagnosed usually 
with the help of clinical signs and histopathological diagnosis. Usual 
mechanisms include reactive drug metabolites and immunological 
reactions. Interactions between FAS (CD 95) and CD95 ligand are said 
to play a major role. This interaction takes place in the epidermal layer 
of the skin. The TEN is more common in women compared to men while 
the reverse is true in case of SJS. Antibiotics have an incidence of 34% in 
causing SJS followed by analgesics with an incidence of 33% [6].
Aceclofenac is a NSAIDs mainly used in the management of pain in 
rheumatic disorders. It acts by inhibiting the cyclooxygenase enzyme 
system thereby inhibiting prostaglandins synthesis. It helps in reducing 
inflammation as well as in pain control. It is associated with side 
effects which include gastrointestinal (GI) disturbances, paresthesias, 
vertigo, and tremor. It is also known to cause cutaneous adverse 
reactions ranging from rashes, pruritus, urticaria, and hypersensitivity 
reactions [7]. There are only few case reports on Aceclofenac-induced 
Stevens-Johnson’s syndrome/toxic epidermal necrolysis [8,9]. 
According to severe cutaneous adverse reactions to drugs, study 
group piroxicam and tenoxicam had the highest risk of SJS/TEN with 
diclofenac and ibuprofen having the lowest risk. According to a study 
by Lapeyre-Mestre et al., Aceclofenac caused many adverse reactions 
including GI disturbances and cutaneous reactions, but liver toxicity 
was found to be the most common reported adverse reaction [10]. 
There are many prognostic factors for SJS, but those of paramount 
important include age at diagnosis, extent of skin necrolysis, and 
serum urea level [9]. Mortality with SJS was found to be around 1 to 
3% compared to higher mortality rates observed with TEN [9]. A large 
multicenter study also revealed early administration of glucocorticoids 
together with withdrawal of offending agent helps in better treatment 
prognosis and patient survival rates [9].
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In our patient, the lesions appeared within 1 day of treatment with 
Aceclofenac. Other causes of SJS/TEN were ruled including history 
of intake of drugs known to cause SJS/TEN. Aceclofenac was stopped 
immediately and the patient was started on Wysolone 20 mg along 
with proper treatment of skin lesions along with supportive measures 
which included electrolyte management. Causality assessment was 
done using Naranjo’s scale [11], and a probable causal relationship 
was established. The adverse drug reaction was found be moderately 
severe and preventable as per Hartwig’s scale and Thornton’s scale, 
respectively [12,13].
CONCLUSION
Since SJS/TEN is a life-threatening cutaneous reaction leading to 
mortality, proper care of the patient along with stopping the offending 
agent after ruling out other causes should be of foremost importance. 
Further, clinical trial can be done in India to find out the incidence of 
SJS/TEN associated with NSAIDs.
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